Organovo Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	3.6yrs

Actualizaciones recientes de la dirección

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

CEO

Organovo Holdings no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Keith Murphy	Executive Chairman	3.8yrs	US$789.99k	1.01% $ 100.9k
Thomas Hess	President & CFO	2.5yrs	US$199.32k	sin datos
Vaidehi Joshi	Director of Discovery Biology & Director	2yrs	US$119.05k	0.20% $ 19.6k
Curtis Tyree	Senior Vice President of Strategy & Business Development	2.2yrs	sin datos	sin datos

2.2yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ONVO se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Keith Murphy	Executive Chairman	3.8yrs	US$789.99k	1.01% $ 100.9k
Vaidehi Joshi	Director of Discovery Biology & Director	2.1yrs	US$119.05k	0.20% $ 19.6k
Glenn Prestwich	Scientific Advisor	no data	sin datos	sin datos
Adam Stern	Independent Director	3.8yrs	US$124.15k	0.20% $ 19.6k
David Mooney	Scientific Advisor	no data	sin datos	sin datos
Gordana Novakovic	Scientific Advisor	no data	sin datos	sin datos
K. Kent	Scientific Advisor	no data	sin datos	sin datos
Alison Milhous	Independent Director	3.6yrs	US$132.25k	0.20% $ 19.6k
Douglas Cohen	Lead Independent Director	3.6yrs	US$132.25k	0.31% $ 31.6k
David Gobel	Independent Director	3.6yrs	US$132.25k	0% $ 0

3.6yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de ONVO se considera experimentada (3.6 años de antigüedad promedio).

Organovo Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

High number of new and inexperienced directors

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

High number of new and inexperienced directors

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

High number of new and inexperienced directors

Recent updates

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad